A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
Status:
Recruiting
Trial end date:
2022-08-11
Target enrollment:
Participant gender:
Summary
This is a Phase 1 cohort, dose-escalation, dose-expansion study of PRT543 in patients with
advanced cancers who have exhausted available treatment options. The purpose of this study is
to define a safe dose and schedule to be used in subsequent development of PRT543.